Danaher’s post-earnings selloff prices transient bioprocessing delays and Masimo dilution, creating a discounted entry into a high-quality recurring-revenue compounder.
Overview
Danaher is a focused life sciences and diagnostics compounder operating through Biotechnology, Life Sciences, and Diagnostics after spinning off its environmental and applied solutions business. It sells high-value instruments and regulated consumables to biopharma companies, clinical laboratories, hospitals, CDMOs, and research institutions. **Approximately 80% of revenue is recurring**, supported by an installed base whose specified consumables are difficult and costly to replace. The company’s moat combines regulatory lock-in, workflow integration, leading brands such as Cytiva and Cepheid, and the Danaher Business System. Q2 2026 revenue rose 5.5% year over year to $6.265 billion, adjusted EPS increased 8.0% to $1.94, and both exceeded consensus. Management raised full-year adjusted EPS guidance to $8.45–$8.60, implying nearly 10.0% growth, while maintaining 3.0%–4.0% core revenue guidance. The stock nevertheless fell to $174.54 after delayed chromatography shipments and Diagnostics margin dilution from Masimo. At 20.46x forward P/E versus a 26.5x ten-year average, valuation discounts temporary issues. The principal catalysts are conversion of delayed bioprocessing orders, Masimo synergies, StatLab integration, and margin recovery.